Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Biotech firm Gilead Sciences has announced plans to voluntarily withdraw the US accelerated approval for Trodelvy ...

Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Perrigo Company (PRGO – Research Report) today and set a price target of ...

DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

US drugmakers Gilead Sciences (Nasdaq: GILD) and Merck & Co (NYSE ... Life Sciences service that brings together a daily ...

From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, ...

Asia Pacific: Operators in Asia Pacific will make up 7% of the five-year new jet deliveries. APAC is returning to typical fleet growth after several years of decline throughout the pandemic. There is ...